glp 1 agonist cardiovascular outcomes and mortality with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Cardiovascular Actions and Clinical Outcomes

All of this started with pramlintide in the 1990s

Healing Peptides: 8-12 Weeks BPC-157 & TB-500 : A standard cycle is 8-12 weeks

Tirzepatide, in contrast, may address the root cause: metabolic dysfunction

doi: 10.1007/s00380-020-01564-6

Vegan Friendly & Gluten Free

Egrifta SV launched commercially in 2020 March 25, 2025 Egrifta WR (tesamorelin F8) Approval Ready-to-use formulation approved no reconstitution required, improved patient convenience Approved Indication Tesamorelin (Egrifta) is specifically FDA-approved for: Indication: Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy HIV-associated lipodystrophy is a metabolic condition causing abnormal fat distribution, particularly visceral adipose tissue (VAT) accumulation around abdominal organs